Gil Roth10.09.13
Phase I
Medivir posts new seven-day data of MIV-711 in osteoarthritis . . . read more
Portola begins proof-of-concept for SyK/JAK inhibitor . . . read more
Phase II
Alkermes aligns with FDA on development plans . . . read more
Allegro cleared for ophthalmic trials . . . read more
Phase III
Pfizer releases topline data for JAK inhibitor . . . read more
TMC enrolls first Angiomax PEI patient . . . read more
Filings
Bayer PAH/CTEPH drug approved . . . read more
BDSI Files Bunavail NDA . . . read more
Medivir posts new seven-day data of MIV-711 in osteoarthritis . . . read more
Portola begins proof-of-concept for SyK/JAK inhibitor . . . read more
Phase II
Alkermes aligns with FDA on development plans . . . read more
Allegro cleared for ophthalmic trials . . . read more
Phase III
Pfizer releases topline data for JAK inhibitor . . . read more
TMC enrolls first Angiomax PEI patient . . . read more
Filings
Bayer PAH/CTEPH drug approved . . . read more
BDSI Files Bunavail NDA . . . read more